aPen- and insulin-naive T2DM patients inadequately controlled on OADs were enrolled in a 4-week, multicenter, open-label, single-arm, phase 3b study to evaluate the ease of use/ease of learning of the Toujeo® SoloStar® pen. On day 1, patients were trained on use of the device. Only patients who completed the training and demonstrated a successful injection without assistance were eligible for this study (n=40). Toujeo® was Injected once-daily in the evening. Patients were titrated to a target SMPG of 80-100 mg/dL. Study limitations: potential bias could have been Introduced due to the small population and the study's short duration; however, the study was designed to minimize such bias.
|1 box provides ...||Up to 45 Units/day (total supply dispensed: 4.5 mL)|
|2 boxes provide ...||46-90 Units/day (total supply dispensed: 9 mL)|
|3 boxes provide ...||91-135 Units/day (total supply dispensed: 13.5 mL)|
Hypothetical patient profile. Individual results may vary.